Biologically active peptides and their uses

Peptides with specific sequences enhance cartilage regeneration and prevent osteoporosis by promoting ECM synthesis and inhibiting inflammation and osteoclast activity, addressing the inefficiencies and side effects of current treatments.

JP2024542102AActive Publication Date: 2024-11-13CAREGEN
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024526613
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-04
Filing Date
2022-10-28
Publication Date
2024-11-13
Estimated Expiration
2042-10-28

AI Technical Summary

Technical Problem

Current medical methods for regenerating damaged cartilage are invasive, costly, and inefficient, while existing anti-inflammatory and osteoporosis treatments have significant side effects and lack selectivity.

Method used

Development of peptides with specific amino acid sequences, such as SEQ ID NO:1, that promote cartilage regeneration, inhibit inflammation, and suppress osteoclast activity, which can be administered as pharmaceutical compositions or functional health foods.

Benefits of technology

The peptides effectively enhance cartilage regeneration, reduce inflammation, and prevent osteoporosis by promoting ECM synthesis, suppressing inflammatory cytokines, and inhibiting osteoclast differentiation, offering a safer and more effective treatment approach.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542102000001_ABST
    Figure 2024542102000001_ABST
Patent Text Reader

Abstract

The present invention relates to novel peptides having various physiological activities and their uses. The novel peptides according to the present invention can not only induce an increase in joint components in chondrocytes and increase chondrocyte differentiation and extracellular matrix production in mesenchymal stem cells, but also inhibit an increase in inflammatory cytokines and inflammatory proteins, and inhibit the differentiation and formation of osteoclasts, and therefore can be usefully used as an active ingredient in pharmaceutical compositions for regenerating cartilage or preventing or treating inflammatory diseases or osteoporosis, or in health functional foods for improving the above symptoms.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to peptides having various physiological activities and uses thereof. [Background technology]

[0002] Generally, cartilage tissues that form the joints of vertebrates do not have blood vessels, nerves, or lymphatic tissues, and therefore cannot be regenerated normally in vivo once damaged. When cartilage tissues of such joints are damaged, it causes severe pain and limits daily activities, and when it becomes chronic, it induces fatal degenerative arthritis, hindering normal life and occupational activities. Therefore, the self-recovery and regeneration of damaged articular cartilage is very limited. Although various medical methods have been tried, it is still insufficient to restore hyaline cartilage, which is articular cartilage, to a natural state.

[0003] Clinically used surgical methods for regenerating cartilage include inducing the differentiation of stem cells into chondrocytes, osteochondral transplantation, where autologous or allogeneic cartilage tissue is transplanted into the cartilage defect site, microfracture, where damaged cartilage is carefully scraped away to expose the subchondral bone, and holes are drilled at regular intervals through which bone marrow cells leak out and are allowed to regenerate into cartilage tissue, chondrocyte transplantation, where chondrocytes are transplanted into the cartilage defect site to induce cartilage regeneration, and autologous chondrocyte transplantation to treat damaged articular cartilage.

[0004] However, when using the above method, surgery is required for harvesting chondrocytes and transplanting the in vitro cultured chondrocytes back into the damaged part of the articular cartilage, so that the two surgeries result in pain, aftereffects, and a large economic burden for the patient, and the surgical procedure is complicated. In addition, most of the harvested chondrocytes are obtained from fully grown adults, and since the harvested cells do not proliferate or grow vigorously, it takes a considerable amount of time to obtain the number of cells required for transplantation during in vitro cell culture. If the cells lose their differentiation ability and do not proliferate at all, no treatment is performed, and since the chondrocytes are cultured in vitro, there is a problem that the phenotype of the cells changes, so that there is a demand for the development of a technology that can regenerate cartilage tissue more effectively.

[0005] Meanwhile, inflammation is a type of defense reaction of living tissue that occurs when tissues or cells are damaged or injured, or when they become infected by an external source of infection (virus, bacteria, fungus, allergy-inducing substance, etc.), and refers to a series of complex conditions caused by immune cells involved in various immune reactions that gather around the damaged or infected area and the inflammatory factors they secrete.

[0006] Currently known therapeutic agents for inflammatory diseases include dexamethasone and cortisone, which use adrenal cortex hormone components, but these have the problem of being highly toxic and causing side effects such as edema, although they are active as therapeutic agents. In addition, it has been reported that they do not selectively act on the cause of inflammation, so they may cause severe immunosuppression and may cause problems. As described above, the use of drugs containing steroid components to treat inflammatory diseases is accompanied by side effects and problems, so there is an urgent need to develop a therapeutic agent for inflammatory diseases that uses drugs containing non-steroid components and has a stable anti-inflammatory treatment effect without side effects.

[0007] At the same time, various compounds that inhibit bone resorption or promote bone formation have been disclosed as treatments for osteoporosis. However, since these conventional treatments often have toxicity and side effects, there is a demand for the development of new substances to replace them. Summary of the Invention [Problem to be solved by the invention]

[0008] An object of the present invention is to provide peptides having diverse physiological activities.

[0009] Another object of the present invention is to provide a pharmaceutical composition for cartilage regeneration, or for preventing or treating inflammatory diseases or osteoporosis, which comprises the peptide as an active ingredient.

[0010] Another object of the present invention is to provide a health functional food containing the peptide as an active ingredient for cartilage regeneration, or for preventing or improving inflammatory diseases or osteoporosis.

[0011] Another object of the present invention is to provide a method for treating, preventing, or ameliorating osteoporosis, comprising administering a therapeutically effective amount of the peptide to a subject.

[0012] Another object of the present invention is to provide uses of the peptide for cartilage regeneration, and for the treatment, prevention, or amelioration of inflammatory diseases or osteoporosis. [Means for solving the problem]

[0013] To achieve the above object, one aspect of the present invention provides a peptide comprising the amino acid sequence of SEQ ID NO:1.

[0014] In one embodiment, the peptide of the present invention may have various biological activities such as cartilage regeneration activity, anti-inflammatory activity, osteoporosis suppression activity, and the like.

[0015] In one embodiment, the peptide of the present invention can promote differentiation of stem cells, such as umbilical cord blood-derived stem cells, peripheral blood-derived stem cells, bone marrow-derived stem cells, and mesenchymal stem cells, preferably mesenchymal stem cells, into chondrocytes.

[0016] In one embodiment, the peptide of the present invention can increase the synthesis of extracellular matrix (ECM) in chondrocytes and can increase the expression of genes related to the production of ECM, such as collagen type II (COL2A1), aggrecan (ACAN), PCP (Proteoglycan Core Protein), etc., in chondrocytes.

[0017] In another embodiment, the peptide of the present invention may suppress the expression of inflammatory cytokines, including, but not limited to, TNFα, IL-1β, COX2, IL-6, IL-17, and IFNγ.

[0018] In other embodiments, the peptides of the present invention may, for example, promote differentiation of macrophages into osteoclasts.

[0019] Another aspect of the present invention provides a pharmaceutical composition for cartilage regeneration, or for preventing or treating inflammatory diseases or osteoporosis, comprising a peptide comprising the amino acid sequence of SEQ ID NO:1 as an active ingredient.

[0020] Another aspect of the present invention provides a health functional food for cartilage regeneration, or for preventing or ameliorating inflammatory diseases or osteoporosis, which comprises a peptide having the amino acid sequence of SEQ ID NO:1 as an active ingredient.

[0021] Another aspect of the invention provides a method of treating, preventing, or ameliorating osteoporosis in a subject, comprising administering to the subject, e.g., an osteoporosis patient, a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:1.

[0022] Another aspect of the invention provides a method of treating, preventing, or ameliorating an inflammatory disease in a subject, comprising administering to the subject, e.g., a patient suffering from an inflammatory disease, a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:1.

[0023] Another aspect of the invention provides a method of regenerating cartilage in a subject, comprising administering to the subject, e.g., a patient in need of cartilage regeneration, a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:1.

[0024] Another aspect of the present invention provides the use of a peptide comprising the amino acid sequence of SEQ ID NO:1 for the treatment, prevention, or amelioration of osteoporosis or an inflammatory disease.

[0025] Another aspect of the present invention provides the use of a peptide comprising the amino acid sequence of SEQ ID NO:1 for cartilage regeneration. Effect of the Invention

[0026] The peptide provided by the present invention can induce an increase in joint components in chondrocytes, increase chondrocyte differentiation and extracellular matrix (ECM) production in mesenchymal stem cells, inhibit an increase in inflammatory cytokines and inflammatory proteins, and inhibit the differentiation and formation of osteoclasts. Therefore, the peptide can be usefully used as an active ingredient in pharmaceutical compositions for regenerating cartilage or preventing or treating inflammatory diseases or osteoporosis, or in health functional foods for improving the symptoms.

[0027] However, the effects of the present invention are not limited to those mentioned above, and other effects not mentioned will be clearly understood by those skilled in the art from the following description. [Brief description of the drawings]

[0028] [Figure 1a] 1 shows molecular weight analysis results illustrating the synthesis of a peptide of the present invention. [Figure 1b] 1 shows molecular weight analysis results illustrating the synthesis of a peptide of the present invention. [Diagram 2] 1 shows Alcian blue stained photographs showing the effect of the peptide of the present invention on ECM synthesis in chondrocytes. [Diagram 3] 1 shows electrophoretic photographs and a graph showing the effect of the peptide of the present invention on the expression of ECM-related genes in chondrocytes. [Figure 4] FIG. 1 shows Alcian blue stained photographs showing the effect of the peptide of the present invention on the synthesis of ECM molecules in three-dimensional culture of chondrocytes, where Non indicates the group not treated with the peptide of the present invention. [Diagram 5] 1 shows Alcian blue staining photographs showing the effect of the peptide of the present invention on the differentiation of mesenchymal stem cells (MSCs) into chondrocytes and the production of ECM. [Figure 6a] Electrophoretic photographs showing the effect of the peptide of the present invention on the production of SOX9 protein, a regulator of ECM synthesis, in mesenchymal stem cells, showing the results after 3 days of treatment with the peptide of the present invention. Non indicates a group not treated with the peptide of the present invention, and CM indicates a positive control group. [Figure 6b] Electrophoretic photographs showing the effect of the peptide of the present invention on the production of SOX9 protein, a regulator of ECM synthesis, in mesenchymal stem cells, showing the results after 7 days of treatment with the peptide of the present invention. Non indicates the group not treated with the peptide of the present invention. [Figure 6c] Electrophoretic photographs showing the effect of the peptide of the present invention on the production of SOX9 protein, a regulator of ECM synthesis, in mesenchymal stem cells, showing the results after 14 days of treatment with the peptide of the present invention, where CM indicates the positive control group and Non indicates the group not treated with the peptide of the present invention. [Figure 7a] Electrophoretic photographs showing the effect of the peptide of the present invention on the expression of ECM-related genes in mesenchymal stem cells, showing the results after 3 days of treatment with the peptide of the present invention. Non indicates a group not treated with the peptide of the present invention, and CM indicates a positive control group. [Figure 7b]Electrophoretic photographs showing the effect of the peptide of the present invention on the expression of ECM-related genes in mesenchymal stem cells, showing the results after 7 days of treatment with the peptide of the present invention. Non indicates a group not treated with the peptide of the present invention, and CM indicates a positive control group. [Figure 7c] Electrophoretic photographs showing the effect of the peptide of the present invention on the expression of ECM-related genes in mesenchymal stem cells, showing the results after 14 days of treatment with the peptide of the present invention. Non indicates a group not treated with the peptide of the present invention, and CM indicates a positive control group. [Figure 8] 1 shows electrophoretic photographs and a graph showing the effect of the peptide of the present invention on the expression of inflammatory cytokines in macrophages in which an inflammatory response has been induced, in which CON indicates a group not treated with the peptide of the present invention. [Figure 9] 1 shows electrophoretic photographs and graphs showing the effect of the peptide of the present invention on the production of inflammatory protein COX2 in macrophages in which an inflammatory response has been induced, in which CON indicates the group not treated with the peptide of the present invention. [Figure 10a] 1 shows stained photographs and a graph showing the effect of the peptide of the present invention on differentiation of macrophages into osteoclasts, and shows that the peptide of the present invention inhibits differentiation into osteoclasts induced by RANKL. Non and CON indicate groups not treated with the peptide of the present invention. [Figure 10b] 1 shows staining photographs and a graph showing the effect of the peptide of the present invention on differentiation of macrophages into osteoclasts, and the graph shows that the peptide of the present invention does not show toxicity in mouse macrophages. Non and CON represent groups not treated with the peptide of the present invention. [Figure 10c] 1 shows stained photographs and a graph showing the effect of the peptide of the present invention on differentiation of macrophages into osteoclasts, and the graph shows that the peptide of the present invention inhibits the activity of TRAP, a marker of osteoclasts, in a density-dependent manner. Non and CON indicate groups not treated with the peptide of the present invention. [Figure 11] FIG. 1 shows stained photographs showing the effect of the peptide of the present invention on differentiation of macrophages into osteoclasts, where CON indicates the group not treated with the peptide of the present invention. [Figure 12] 1 shows immunofluorescence staining photographs showing the effect of the peptide of the present invention on the formation of an actin ring, which is essential for differentiation of macrophages into osteoclasts. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] The present invention will be described in detail below.

[0030] 1. Peptides of the Invention The present invention provides peptides having useful physiological activities, for example, cartilage regeneration activity, anti-inflammatory activity, or osteoporosis suppression activity.

[0031] The peptide means a polymer consisting of two or more amino acids linked by peptide bonds. If the size of the peptide itself is too large, it has the disadvantage that it cannot be effectively delivered to target tissues or cells or has a short half-life and disappears in the body in a short period of time. Therefore, the peptide of the present invention consists of 20 or less amino acids, for example, 15 or less, or 12 or less.

[0032] The peptide of the present invention may include or consist of the amino acid sequence of SEQ ID NO: 1. In one embodiment of the present invention, the peptide of the present invention may include all amino acid variants or fragments having a sequence different from SEQ ID NO: 1, in which the amino acid residues constituting the amino acid sequence of SEQ ID NO: 1 are modified by deletion, insertion, substitution, or a combination thereof, within a range that does not affect useful biological activities, such as cartilage regeneration activity, anti-inflammatory activity, or osteoporosis suppression activity. Amino acid exchange at the peptide level that does not overall change the biological activity of the peptide, such as cartilage regeneration activity, anti-inflammatory activity, or osteoporosis suppression activity, is known in the art. In some cases, the peptide may be modified by phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, etc. Thus, the present invention includes peptides having substantially the same amino acid sequence as a peptide including or consisting of the amino acid sequence of SEQ ID NO: 1, and variants or active fragments thereof. The substantially identical protein means an amino acid sequence having a sequence homology of 75% or more, for example, 80% or more, 90% or more, 95% or more, 98% or more, or 99% or more, respectively, with the amino acid sequence of SEQ ID NO: 1. The peptide of the present invention may further include a targeting sequence, a tag, a labeled residue, or an amino acid sequence specifically produced to increase half-life or peptide stability.

[0033] In addition, the peptide of the present invention can be obtained by various methods widely known in the art. In one embodiment of the present invention, the peptide of the present invention may be prepared by a method of synthesis in vitro using polynucleotide recombination and a protein expression system, or by chemical synthesis such as peptide synthesis, and a cell-free protein synthesis method.

[0034] In addition, a protecting group may be attached to the N-terminus or C-terminus of the peptide of the present invention to obtain better chemical stability, enhanced pharmacological properties (half-life, water absorption, potency, efficacy, etc.), altered specificity (e.g., broader biological activity spectrum), and reduced antigenicity. For example, the protecting group may be an acetyl group, a fluorenylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, or a polyethylene glycol (PEG), and may include any component that can enhance the modification of the peptide, particularly the stability of the peptide, without limitation. The term "stability" is used to mean not only in vivo stability that protects the peptide of the present invention from attack by in vivo protease, but also storage stability (e.g., room temperature storage stability).

[0035] In the present invention, the term "cartilage regeneration activity" is used to mean a series of in vivo or in vitro activities required for cartilage formation, without limitation. In one embodiment of the present invention, the cartilage regeneration activity may include an activity of promoting the synthesis of components constituting cartilage, such as ECM, in chondrocytes. In another embodiment of the present invention, the cartilage regeneration activity may include an activity of increasing the expression of ECM regulators in chondrocytes. In another embodiment of the present invention, the cartilage regeneration activity may include an activity of promoting the differentiation of stem cells, such as umbilical cord blood-derived stem cells, peripheral blood-derived stem cells, bone marrow-derived stem cells, and mesenchymal stem cells, preferably mesenchymal stem cells, into chondrocytes. In another embodiment of the present invention, the cartilage regeneration activity may include an activity of promoting the production of ECM and ECM regulators in chondrocytes or stem cells, preferably mesenchymal stem cells, or promoting the expression of genes related thereto.

[0036] In order to confirm the cartilage regeneration effect of the peptide of the present invention, in a preferred embodiment of the present invention, human chondrocytes were treated with a peptide comprising the amino acid sequence of SEQ ID NO: 1 and the formation of ECM was confirmed. As a result, it was confirmed that treatment with the peptide of the present invention promoted ECM production in chondrocytes (see FIG. 2).

[0037] In another embodiment of the present invention, human chondrocytes were treated with a peptide containing the amino acid sequence of SEQ ID NO: 1 to examine the level of expression of genes involved in ECM formation. As a result, it was confirmed that treatment with the peptide of the present invention promoted the expression of COL2A1, COMP, and PCP genes present in chondrocytes (see Figure 3).

[0038] In another embodiment of the present invention, the formation of ECM was confirmed by treating human chondrocytes in 3D culture with a peptide containing the amino acid sequence of SEQ ID NO: 1. It was confirmed that treatment with the peptide of the present invention increased the production of signaling proteins involved in the formation of ECM in chondrocytes (see Figure 4).

[0039] In addition, in another embodiment of the present invention, the differentiation of mesenchymal stem cells into chondrocytes and the production of ECM were examined. As a result, it was confirmed that treatment with the peptide of the present invention promoted the differentiation of mesenchymal stem cells into chondrocytes and the production of ECM (see FIG. 5).

[0040] In another embodiment of the present invention, mesenchymal stem cells were treated with a peptide containing the amino acid sequence of SEQ ID NO: 1 to examine the level of expression of genes involved in ECM production and ECM formation. As a result, it was confirmed that treatment with the peptide of the present invention promoted the production of ECM present in mesenchymal stem cells and the expression of genes and proteins that regulate ECM production (see Figures 6a to 6c and Figures 7a to 7c).

[0041] On the other hand, the peptide of the present invention can have physiological activities other than cartilage regeneration, for example, anti-inflammatory activity.

[0042] In the present invention, "anti-inflammatory activity" is used to mean an activity to suppress inflammation without limitation, and the inflammation is a kind of defense reaction of biological tissue against a certain stimulus, and means a pathological state of abscess formed when tissue or cells are damaged or infected with various infectious sources such as bacteria, fungi, viruses, allergens derived from the outside. The inflammatory reaction shows a complex physiological reaction such as activation of enzymes, secretion of inflammatory mediators, infiltration of body fluids, cell migration, tissue destruction, etc., which are shown in association with inflammatory mediators and immune cells in local blood vessels and body fluids, and external symptoms such as erythema, edema, fever, pain, etc. The peptide of the present invention has an activity to suppress inflammation, and therefore has an effect of reducing and improving a series of pathological conditions and symptoms as described above.

[0043] In addition, the peptide of the present invention can suppress the expression of inflammatory cytokines or inflammatory proteins. When a wound is caused by an inflammatory reaction or an external infectious agent enters the body through the wound site, white blood cells responsible for the initial stage of immune reaction gather around the wound site or the infectious agent, and inflammation-related cytokines and proteins are expressed and secreted to induce an inflammatory reaction. Therefore, by suppressing the expression of inflammatory cytokines or inflammatory proteins, anti-inflammatory activity can be exhibited, and the anti-inflammatory activity and inflammation suppressing effect of the peptide of the present invention can be confirmed by confirming the expression amount of the inflammatory cytokines and proteins.

[0044] The inflammatory cytokine may be one or more selected from the group consisting of TNFα, IL-6, IL-17, IL-1β, and IFNγ. TNFα is an abbreviation of "Tumor Necrosis Factor α" and is a cytokine produced and secreted from macrophages and various cells activated during immune responses to bacterial infections or tumor diseases. It is known as a main mediator of inflammatory responses and plays an important role in inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis, Crohn's disease, psoriasis, and ankylosing spondylitis (AS). IL-6 (interleukin 6) is a cytokine produced by macrophages and various lymphocytes, and is known to promote inflammatory responses and to induce inflammatory diseases when produced excessively. IL-17 (interleukin 17) is also a pro-inflammatory cytokine and is produced by Th17 cells to induce or mediate inflammatory responses. The IFNγ (interferon γ) may be produced by T lymphocytes and macrophages, and is secreted in response to infection by viruses or bacteria that invade from the outside, and is known to play a role in autoimmune or autoinflammatory diseases. Therefore, the peptide of the present invention has an effect of suppressing inflammation by suppressing the expression of such inflammatory cytokines and suppressing the secretion of the expressed cytokines.

[0045] In addition, the peptide of the present invention can suppress the expression of Cox2. The Cox2 (cyclooxygenase 2) is an enzyme involved in stimulating the biosynthesis process of prostaglandins, and may be expressed under the control of NF-κB, regulating inflammatory responses. Cox2 is a protein that is hardly expressed under normal conditions, but is rapidly expressed in response to stimuli such as cytokines, inflammatory factors, and endotoxins. Therefore, the anti-inflammatory activity of the peptide of the present invention can be confirmed by checking the expression level of the Cox2 gene and the amount of Cox2 protein, and the peptide of the present invention exhibits the effect of suppressing inflammation by suppressing the expression of Cox2.

[0046] In order to confirm the inflammation suppressing effect of the peptide of the present invention, in a preferred embodiment of the present invention, mouse macrophages were treated with a peptide comprising the amino acid sequence of SEQ ID NO: 1 together with inflammation-inducing cytokines to examine the amount of Cox2 protein. As a result, it was confirmed that although the treated inflammation-inducing cytokines induced an inflammatory response in the cells, the amount of Cox2 protein was reduced by treatment with the peptide of the present invention (see FIG. 8).

[0047] In addition, in order to confirm the effect of reducing the expression levels of inflammation-related genes by treatment with the peptide of the present invention, in a preferred embodiment of the present invention, mouse macrophages were treated with inflammatory cytokines together with a peptide having the amino acid sequence of SEQ ID NO: 1, and the mRNA levels of TNFα, IL-1β, and Cox2 genes were examined. As a result, it was confirmed that although the inflammatory response of the cells was induced by the inflammatory cytokines treated, the expression levels of the inflammatory cytokines and related enzyme genes were reduced by treatment with the peptide of the present invention (see FIG. 9).

[0048] Therefore, it is clear that the peptide of the present invention has anti-inflammatory activity that can reduce and improve inflammatory responses by reducing the expression and secretion of inflammatory cytokines such as TNFα, IL-6, IL-17, IL-1β, and IFNγ, which can promote inflammatory responses, and by suppressing the expression of inflammation-related factors such as Cox2, and therefore the peptide of the present invention can be usefully used as an active ingredient of a composition for preventing, treating, or improving inflammatory diseases induced by inflammation or accompanied by inflammatory responses.

[0049] At the same time, the peptide of the present invention can have physiological activities other than cartilage regeneration, for example, osteoclast-inhibiting activity.

[0050] In one embodiment of the present invention, mouse macrophages were treated with a peptide containing the amino acid sequence of SEQ ID NO: 1 together with RANKL (Receptor Activator of Nuclear factor Kappa-B ligand), which induces differentiation into osteoclasts, to confirm the differentiation into osteoclasts and the activity of proteins related to the differentiation into osteoclasts. As a result, it was confirmed that treatment with the peptide of the present invention reduced the differentiation into osteoclasts and the expression of proteins related thereto, and also inhibited the formation of actin rings, which are essential for the differentiation of osteoclasts (see Figures 10a to 10c, 11, and 12).

[0051] Increased osteoclast activity is closely related to osteoporosis, and therefore the peptide of the present invention can be useful in preventing or treating osteoporosis by suppressing osteoclast activity.

[0052] 2. Pharmaceutical compositions containing the peptides of the present invention Another aspect of the present invention provides a pharmaceutical composition for cartilage regeneration, comprising a peptide comprising the amino acid sequence of SEQ ID NO:1 as an active ingredient.

[0053] Yet another aspect of the present invention provides a pharmaceutical composition for preventing or treating an inflammatory disease, comprising a peptide comprising the amino acid sequence of SEQ ID NO:1 as an active ingredient.

[0054] Yet another aspect of the present invention provides a pharmaceutical composition for preventing or treating osteoporosis, which comprises a peptide comprising the amino acid sequence of SEQ ID NO:1 as an active ingredient.

[0055] Since the peptide containing the amino acid sequence of SEQ ID NO:1 is the same as the peptide described in the above section "1. Peptides of the present invention," the specific description will be given in the above section "1. Peptides of the present invention," and only the components unique to the pharmaceutical composition will be described below.

[0056] According to one embodiment of the present invention, the peptide of the present invention has the effect of promoting cartilage regeneration, and therefore, a pharmaceutical composition containing the peptide as an active ingredient can be used for cartilage regeneration.

[0057] According to another embodiment of the present invention, the peptide of the present invention has the effect of inhibiting the expression or secretion of inflammation-related cytokines or inflammation-related factors, and therefore, a pharmaceutical composition containing the peptide as an active ingredient can be used for preventing or treating inflammatory diseases.

[0058] According to another embodiment of the present invention, the peptide of the present invention has the effect of inhibiting the differentiation and activity of osteoclasts, and therefore, a pharmaceutical composition containing the peptide as an active ingredient can be used to prevent or treat osteoporosis.

[0059] In the present invention, the inflammatory disease may refer to a pathological condition in which inflammation induced by neutrophil chemotaxis occurs in leukocytes, and may include, without limitation, any disease caused by or accompanied by an inflammatory response. For example, the inflammatory disease may be rhinitis, bronchitis, periodontitis, pancreatic colitis, gastritis, gastric ulcer, inflammatory skin disease, atopic dermatitis, encephilitis, sepsis, inflammatory colitis, chronic obstructive pulmonary disease, pulmonary hemophilic shock, pulmonary fibrosis, undifferentiated spondyloarthropathy, undifferentiated arthropathy, arthritis, inflammatory osteolysis, chronic inflammatory disease caused by chronic viral or bacterial infection, colitis, inflammatory bowel disease, type 1 diabetes, rheumatoid arthritis, reactive arthritis, and the like. The disease may be, but is not limited to, inflammatory bowel disease, osteoarthritis, osteoarthritis, psoriasis, scleroderma, osteoporosis, atherosclerosis, myocarditis, endocarditis, pericarditis, cystic fibrosis, Hashimoto's thyroiditis, Graves' disease, leprosy, syphilis, Lyme disease, borreliosis, neuro-borreliosis, tuberculosis, sarcoidosis, lupus, discoid lupus, pernio, lupus nephritis, systemic lupus erythematosus, macular degeneration, uveitis, irritable bowel syndrome, Crohn's disease, Sjogren's syndrome, fibromyalgia, chronic fatigue syndrome, chronic fatigue immune deficiency syndrome, myocardial facultative encephalomyelitis, amyotrophic lateral sclerosis, Parkinson's disease, or multiple sclerosis.

[0060] The pharmaceutical composition of the present invention may be used to promote cartilage regeneration, prevent the occurrence of inflammatory diseases by suppressing the expression or secretion of factors that induce inflammatory responses, prevent the occurrence of osteoporosis by suppressing the differentiation of osteoclasts, or inhibit the deterioration of the disease by suppressing the inflammatory response that occurs in damaged or injured cells in patients with the inflammatory disease or the differentiation into osteoclasts in patients with osteoporosis, thereby treating the disease.

[0061] Meanwhile, the pharmaceutical composition containing the peptide of the present invention as an active ingredient may be prepared in a unit dose form or in a multi-dose container by formulating it with a pharma- ceutically acceptable carrier and / or excipient in a manner that can be easily carried out by a person skilled in the art to which the present invention pertains. In this case, the dosage form may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granules, tablets, capsules or gel (e.g., hydrogel), and may further include a dispersant or stabilizer.

[0062] The peptides contained in the pharmaceutical compositions may also be delivered in pharma- ceutically acceptable carriers such as colloidal suspensions, powders, saline solutions, lipids, liposomes, microspheres, or nanospheres, which may be complexed or associated with a delivery vehicle and delivered to the body using delivery systems known in the art, such as lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation agents, polysaccharides, polyamino acids, dendrimers, saponins, adsorption enhancers, or fatty acids.

[0063] In addition, the pharma- ceutically acceptable carrier may include, but is not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, etc. In addition to the above ingredients, the pharmaceutical composition may further include lubricants, wetting agents, sweeteners, flavorings, emulsifiers, suspending agents, preservatives, etc.

[0064] The pharmaceutical composition according to the present invention can be administered orally or parenterally in clinical administration and may be used in the form of a general pharmaceutical preparation. That is, the pharmaceutical composition according to the present invention may be administered in various oral and parenteral dosage forms in clinical administration, and when formulated, it is prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, surfactant, etc. that is commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations are prepared by mixing herbal extracts or herbal fermentation products with at least one or more excipients, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stylate talc are also used. Liquid preparations for oral administration include suspensions, oral liquids, emulsions, syrups, etc., and may include various excipients, such as wetting agents, sweeteners, flavorings, preservatives, etc., in addition to water and liquid paraffin, which are commonly used simple diluents. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions may be used, such as propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases may be used, such as witepsol, macrogol, twin 61, cacao butter, laurin butter, glycerol, and gelatin.

[0065] The pharmaceutical composition of the present invention is administered in a pharma- tically effective amount. In the present invention, the term "pharma- tically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the level of the effective dose may be determined depending on factors including the type and severity of the patient's disease, the activity of the drug, sensitivity to the drug, administration time, administration route, and excretion rate, treatment period, drugs used concomitantly, and other factors well known in the medical field. The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents for inflammatory diseases, and may be administered simultaneously, separately, or sequentially with conventional therapeutic agents, and may be administered singly or in multiple doses. It is important to administer an amount that provides maximum effect at a minimum amount without side effects, taking into consideration all of the above factors, and this can be easily determined by those skilled in the art.

[0066] Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the age, sex, condition, weight, absorbency of the active ingredient in the body, inactivation rate, excretion rate, type of disease, and concomitant drugs of the patient, and may be increased or decreased depending on the administration route, severity of obesity, sex, weight, age, etc. For example, the peptide of the present invention may be administered at about 0.0001 ug to 500 mg, for example, 0.01 ug to 100 mg per kg of patient body weight per day. Also, it may be administered several times a day at regular intervals, for example, divided into two or three times a day, according to the judgment of a doctor or pharmacist.

[0067] 3. Health functional food containing the peptide of the present invention Another aspect of the present invention provides a health functional food for cartilage regeneration, which contains a peptide comprising the amino acid sequence of SEQ ID NO:1 as an active ingredient.

[0068] Yet another aspect of the present invention provides a health functional food for preventing or ameliorating an inflammatory disease, which contains a peptide comprising the amino acid sequence of SEQ ID NO:1 as an active ingredient.

[0069] Yet another aspect of the present invention provides a health functional food for preventing or ameliorating osteoporosis, which contains a peptide comprising the amino acid sequence of SEQ ID NO:1 as an active ingredient.

[0070] Since the peptide containing the amino acid sequence of SEQ ID NO:1 is the same as the peptide described in the above section "1. Peptides of the present invention," the specific explanation will be given by reference to the above section "1. Peptides of the present invention," and only the unique composition of the health functional food will be described below.

[0071] Like the pharmaceutical composition, a health functional food containing the peptide of the present invention as an active ingredient can be useful for regenerating cartilage and for preventing or improving inflammatory diseases or osteoporosis.

[0072] The health functional food may be used before or after the onset of a disease in order to prevent or improve the disease, either simultaneously with or separately from a therapeutic drug.

[0073] In the health functional food of the present invention, the active ingredient may be added directly to the food or used together with other foods or food ingredients, and may be used appropriately by a conventional method. The amount of the active ingredient to be mixed may be appropriately determined depending on the purpose of use (for prevention or improvement). In general, when producing a food or beverage, the composition of the present invention may be added in an amount of preferably 15% by weight or less, more preferably 10% by weight or less, based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or health regulation, the amount may be less than the above range.

[0074] In addition to containing the active ingredient, the health functional food of the present invention may contain other ingredients as essential ingredients without any particular limitation. For example, it may contain various flavorings or natural carbohydrates as additional ingredients like ordinary beverages. Examples of the natural carbohydrates mentioned above may be monosaccharides such as glucose, fructose, etc.; disaccharides such as maltose, sucrose, etc.; and polysaccharides such as dextrin, cyclodextrin, etc., and sugar alcohols such as xylitol, sorbitol, erythritol. As flavorings other than those mentioned above, natural flavorings (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavorings (saccharin, aspartame, etc.) can be advantageously used. The proportion of the natural carbohydrates may be appropriately determined by the selection of a person skilled in the art.

[0075] In addition to the above, the health functional food of the present invention may contain various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants, and thickeners (cheese, chocolate, etc.), pectinic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated drinks, etc. These ingredients may be used independently or in combination, and the proportions of such additives may also be appropriately selected by those skilled in the art.

[0076] The present invention will now be described in more detail with reference to examples.

[0077] However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples.

[0078] [Example 1] Preparation of peptides Using an automated peptide synthesizer (Milligen 9050, Millipore, USA), peptides having the amino acid sequence of SEQ ID NO: 1 shown in Table 1 below were synthesized, and the synthesized peptides were purified and separated using C18 reversed-phase high performance liquid chromatography (HPLC) (Waters Associates, USA). The column used was an ACQUITY UPLC BEH300 C18 (2.1 mm x 100 mm, 1.7 um, Waters Co, USA). As a result of molecular weight analysis using a 3200 QTRAP LC-MS / MS system, it was confirmed that the peptide of the present invention with a molecular weight of 1250.5 Da was synthesized (FIGS. 1a and 1b).

[0079] [Table 1] [Experimental Example 1] Confirmation of promotion of ECM production in chondrocytes by peptide treatment In order to confirm the cartilage regeneration effect of treatment with the peptide of the present invention having the amino acid sequence of SEQ ID NO: 1, human-derived chondrocytes were treated with the peptide of SEQ ID NO: 1, and then the increase in the formation of glycosaminoglycan, a component of ECM, was confirmed.

[0080] For this purpose, the human C28 / I2 chondrocyte cell line was cultured at 3 × 10 3 The cells were distributed into a 96-well plate at a density of cells / well and cultured in DMEM medium (cat.11995-065, Gibco) for 24 hours. After replacing with fresh medium, the peptide of SEQ ID NO:1 was treated at 30, 50, 100, and 150ug / ml. The peptide of SEQ ID NO:1 was treated at each concentration while changing the medium once every 3 days. After removing the medium on the 6th, 60ul of 3.7% formalin was added to the 96-well plate to be stained and fixed for 1 minute. After removing the 3.7% formalin, 70ul of Alcian blue staining solution (50ml of 3% acetic acid + 0.5g of 1% Asian blue 8GX, pH 2.5) was added and incubated at 37°C for 24 hours. Then, the staining solution was removed, washed with triple distilled water, dried, and observed under a microscope.

[0081] As a result, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention promoted the production of ECM in chondrocytes (see FIG. 2).

[0082] [Experimental Example 2] Confirmation of promotion of ECM gene expression in chondrocytes by peptide treatment After treating human-derived chondrocytes with a peptide having the amino acid sequence of SEQ ID NO:1, we confirmed whether there was an increase in mRNA expression of collagen type II (COL2A1), aggrecan (ACAN), proteoglycan core protein (PCP), which are components of the ECM, and the GAPDH gene as a control.

[0083] For this purpose, the human C28 / I2 chondrocyte cell line was cultured at 8.9 × 10 4 The cells were plated into a 6-well plate at a density of cells / well and cultured in DMEM medium (cat.11995-065, Gibco) for 24 hours. After replacing with fresh medium, the cells were treated with peptide of SEQ ID NO:1 at 50 and 100 ug / ml concentrations. The peptide of SEQ ID NO:1 was treated at the different concentrations while changing the medium once every 3 days. After removing the medium on the 9th, the cells were harvested and RNA was isolated. cDNA was synthesized using a cDNA synthesis kit (Intron, Korea), and then PCR was performed for collagen type II, ACAN, PCP, and GAPDH genes using PCR free-mix (Intron, Korea). Primers specific to collagen type II, ACAN, PCP, and GAPDH are as shown in Table 2 below:

[0084] [Table 2] As a result, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention promoted the expression of collagen type II, ACAN, and PCP genes associated with ECM production in chondrocytes (see FIG. 3).

[0085] [Experimental Example 3] Confirmation of promotion of ECM generation in 3D culture of chondrocytes by peptide treatment After treating 3D culture of human-derived chondrocytes with a peptide having the amino acid sequence of SEQ ID NO: 1, it was confirmed whether or not the formation of glycosaminoglycan, a component of ECM, was increased.

[0086] For this purpose, 3 × 10 human C28 / I2 chondrocyte cell line 6 The cells were suspended in 1 ml of alginate solution (1.25% alginic acid, 20 mM HEPES, 150 mM NaCl, pH 7.4), and the alginate solution containing the cells was dropped dropwise into a polymerization solution (100 mM CaCl2, 10 mM HEPES, pH 7.4) to prepare beads. The prepared beads were washed twice with DPBS, and then distributed into conical tubes containing DMEM medium (5% FBS). The peptide of SEQ ID NO: 1 was treated at 100 and 150 ug / ml concentrations, and the medium was changed once every three days, while the peptide of SEQ ID NO: 1 was treated at each concentration. After removing the medium on the 9th, the cells were fixed with 3.7% formaldehyde for 6 hours. The tissue was dehydrated using a tissue processor (EtOH 70%, 80%, 90%, 100% I, II, xylene I, II, 30 minutes each) and embedded to prepare paraffin blocks. The paraffin blocks were sectioned on glass slides to a thickness of 0.4 um and then completely dried for more than 24 hours. The sections were hydrated (xylene I, II, EtOH 100% I, II, 90%, 80%, 70%, 3 minutes each), immersed in running water for 10 seconds, and washed three times. After staining with Alcian blue or Toluidine blue for 1 hour, the sections were immersed in running water for 10 seconds and washed three times. The sections were immersed in EtOH 90%, 100% I, II for 10 seconds, immersed in xylene I, II for 3 minutes each, and then mounted. The sections were dried for more than 24 hours and then observed under a microscope.

[0087] As a result, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention promoted the production of glycosaminoglycan, a component of ECM, in 3D culture of chondrocytes (see FIG. 4).

[0088] [Experimental Example 4] Confirmation of promotion of chondrocyte differentiation and ECM production in mesenchymal stem cells by peptide treatment Adipose-derived mesenchymal stem cells were treated with a peptide having the amino acid sequence of SEQ ID NO: 1, and the effect on chondrocyte differentiation and ECM production of the stem cells was confirmed.

[0089] For this purpose, human AD-MSC (Adipose-Derived Mesenchymal Stem Cell) cells were cultured at 1.5 × 10 3 The cells were distributed into a 96-well plate at a density of cells / well and cultured in DMEM medium (cat.11995-065, Gibco) for 24 hours. After replacing the medium with DMEM medium containing 5% FBS, the peptide of SEQ ID NO:1 was treated at 30, 50, 100, and 150ug / ml. The peptide of SEQ ID NO:1 was treated at each concentration while changing the medium once every three days. After removing the medium on the 15th, 60ul of 3.7% formalin was added to the 96-well plate to be stained and fixed for 1 minute. After removing the 3.7% formalin, 70ul of Alcian blue staining solution (50ml of 3% acetic acid + 0.5g of 1% Alcian blue 8GX, pH 2.5) was added and incubated at 37°C for 24 hours. Then, the staining solution was removed, washed with triple distilled water, dried, and observed under a microscope.

[0090] As a result, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO:1 of the present invention promoted chondrocyte differentiation of adipose-derived mesenchymal stem cells and the production of glycosaminoglycan, a component of ECM (see FIG. 5).

[0091] [Experimental Example 5] Confirmation of ECM regulatory factor expression in mesenchymal stem cells by peptide treatment Adipose-derived mesenchymal stem cells were treated with a peptide having the amino acid sequence of SEQ ID NO: 1, and then the increase in expression of SOX9 protein, an ECM regulator, was confirmed.

[0092] For this purpose, human AD-MSC cells were cultured at 1.5 × 10 3The cells were distributed into a 96-well plate at a density of cells / well and cultured in DMEM medium (cat.11995-065, Gibco) containing 10% FBS for 24 hours. After replacing the medium with DMEM medium containing 5% FBS, the peptide of SEQ ID NO:1 was treated at 50 and 100 ug / ml. The peptide of SEQ ID NO:1 was treated at each concentration while changing the medium once every three days. In this case, a solution containing dexamethasone (100 nM) + ascorbic acid (50 μM) + proline (40 μM) + TGFβ1 (10 ng / ml) + 1X ITS was used as a positive control (CM). After removing the medium on the 3rd, 7th, and 14th days, the cells were harvested and cell lysates were prepared, followed by Western blotting using antibodies against the SOX9 and SOX5 proteins (Millipore, USA).

[0093] As a result, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention increases the production of SOX9 protein, which is an ECM regulator, in adipose-derived mesenchymal stem cells (see FIGS. 6a to 6c).

[0094] [Experimental Example 6] Confirmation of promotion of ECM gene expression in mesenchymal stem cells by peptide treatment After treating adipose-derived mesenchymal stem cells with a peptide having the amino acid sequence of SEQ ID NO:1, we confirmed whether the expression of COMP (Cartilage Oligomeric Matrix Protein), collagen type 11A (COL 11A), PCP, and ACAN (aggrecan), genes related to ECM production, was increased.

[0095] For this purpose, human AD-MSC cells were cultured at 1.5 × 10 3The cells were plated into a 96-well plate at a density of cells / well and cultured in DMEM medium (cat.11995-065, Gibco) containing 10% FBS for 24 hours. After replacing the medium with DMEM medium containing 5% FBS, the peptide of SEQ ID NO:1 was treated at 50 and 100 ug / ml. The peptide of SEQ ID NO:1 was treated at the different concentrations while changing the medium once every 3 days. After removing the medium on days 3, 7, and 11, the cells were harvested and RNA was isolated. cDNA was synthesized using a cDNA synthesis kit (Intron, Korea), and PCR was performed for COMP, COL 11A, PCP, ACAN, and GAPDH genes using PCR Free-Mix (Intron, Korea). The primers specific to COMP, COL 11A, PCP, ACAN, and GAPDH are as shown in Table 3 below:

[0096] [Table 3] As a result, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO:1 of the present invention promoted the expression of COMP, COL11A, PCP, and ACAN genes associated with ECM production in adipose-derived mesenchymal stem cells (see Figures 7a to 7c).

[0097] Considering the results of Experimental Examples 1 to 6 as above, it can be confirmed that the peptide having the base sequence of SEQ ID NO: 1 of the present invention increases the activity of chondrocytes to promote ECM synthesis, increases the expression of genes related to the production of the ECM and ECM regulator genes, promotes differentiation of mesenchymal stem cells into chondrocytes, and also increases the expression of genes related to the production of ECM and ECM regulator genes in mesenchymal stem cells, thereby providing excellent cartilage regeneration effects. In addition, when a larger amount of the peptide of the present invention is used, the above effects are more pronounced, and therefore it can be seen that the cartilage regeneration effects seen from the results of the above experiments are due to the peptide of the present invention.

[0098] [Experimental Example 7] Confirmation of inflammatory cytokine mRNA expression levels in cells induced with TNFα inflammation In order to confirm the anti-inflammatory effect of the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention in addition to the cartilage regeneration activity confirmed in Experimental Examples 1 to 6, the mouse RAW264.7 macrophage cell line was treated with TNFα to induce inflammation, and the expression levels of inflammatory cytokines TNFα and IL-1β, and the Cox2 gene, an inflammation induction marker, were confirmed. The cytokine TNFα was treated to induce inflammation, and since TNFα corresponds to a signaling protein associated with inflammatory responses, IL-1β corresponds to a cytokine that promotes inflammatory responses, and Cox2 is an inflammation-related protein, the level of inflammatory responses can be confirmed by measuring the expression levels of TNFα, Cox2, and IL-1β genes.

[0099] For this purpose, the mouse RAW264.7 cell line was cultured at 2 × 10 5 After dispensing into 6-well plates at a density of cells / well, the cells were cultured in α-MEM medium containing 10% FBS for 24 hours. The medium was replaced with serum-free α-MEM medium (1% penicillin), and then fasted for 6 hours. The cells were treated with peptide of SEQ ID NO: 1 at concentrations of 100 and 150 ug / ml, and then incubated for 1 hour. After 1 hour, the cells were treated with TNF-α at 20 nM, and then incubated for 24 hours. The cells were then harvested and RNA was isolated. cDNA was synthesized using a cDNA synthesis kit (Intron, Korea), and PCR was performed for TNFα, IL-1β, Cox2, and GAPDH genes using PCR free-mix (Intron, Korea). The primers specific to the TNFα, IL-1β, Cox2, and GAPDH genes are as shown in Table 4 below:

[0100] [Table 4] As a result, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention inhibited the expression of inflammatory cytokine genes induced by the treatment of inflammatory cytokines in mouse macrophages (see FIG. 8).

[0101] [Experimental Example 8] Confirmation of inflammatory cytokine mRNA expression levels in cells induced with TNFα inflammation In addition to the results of Experimental Example 7, in order to further confirm the anti-inflammatory effect of treatment with the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention, the mouse RAW264.7 macrophage cell line was treated with TNFα to induce inflammation, and the expression level of COX2 protein, an inflammation induction marker, was examined.

[0102] For this purpose, the mouse RAW264.7 cell line was cultured at 2 × 10 5 After dispensing into 6-well plates at a density of cells / well, the cells were cultured in α-MEM medium containing 10% FBS for 24 hours. After changing to serum-free α-MEM medium (1% penicillin), the cells were fasted for 6 hours. The cells were treated with peptide of SEQ ID NO: 1 at 100 and 150ug / ml and then incubated for 1 hour. After 1 hour, the cells were treated with TNF-α at 20nM and incubated for 24 hours. Then, the cells were harvested and cell lysates were prepared, followed by Western blotting using an antibody against the COX2 protein (Cell Signaling Technology, USA).

[0103] As a result, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention inhibited the increase in inflammatory proteins induced by the treatment of inflammatory cytokines in mouse macrophages (see FIG. 9).

[0104] Considering the results of Experimental Examples 7 and 8, it can be confirmed that even in cells in which an inflammatory response is induced, the amount of proteins and gene expression levels related to the inflammatory response are reduced when the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention is treated, and thus there is an effect of suppressing the inflammatory response. In addition, when a larger amount of the peptide of the present invention is treated, the above-mentioned effect is more pronounced, and therefore it can be seen that the inflammatory response suppression effect seen from the results of the above-mentioned experimental examples is the effect of the peptide of the present invention.

[0105] [Experimental Example 9] Confirmation of the inhibitory effect of RANKL on osteoclast differentiation In addition to the cartilage regeneration activity confirmed in Experimental Examples 1 to 6 and the anti-inflammatory effect confirmed in Experimental Examples 7 and 8, the inhibitory effect of osteoclast differentiation by treatment with a peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention was confirmed.

[0106] <9-1> Confirmation of the osteoclast differentiation inhibitory effect of the peptide of the present invention Mouse RAW264.7 cell line, 1.7 x 10 3 The cells were distributed into a 96-well plate at a density of 10, 30, 50, 100, and 150 ug / ml of peptide of SEQ ID NO: 1 together with RANKL, and then osteoclast differentiation was induced for 4 days. The medium was removed, the cells were fixed for 30 seconds, and washed twice with distilled water. Staining was carried out for 30 minutes at 37°C with 100 ul of TRAP staining solution (acid phosphatase kit, Sigma Aldrich). The staining solution was then removed, the cells were washed three times with distilled water, dried, and observed under a microscope.

[0107] As a result, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention inhibited the differentiation of mouse macrophages into osteoclasts induced by RANKL (see FIG. 10a).

[0108] <9-2> Confirmation of cytotoxicity of the peptide of the present invention The effect of the peptide of the present invention on cell proliferation was confirmed using CCK-8 analysis. The CCK-8 reagent is reduced by the dehydrogenase of cells to produce a colored product, and the proliferation or non-proliferation of cells can be confirmed by the difference in absorbance using this product.

[0109] For this purpose, the mouse RAW264.7 cell line was cultured at 1.7 × 10 3After dispensing into a 96-well plate at a density of cells / well, the cells were cultured in DMEM medium for 24 hours. After 24 hours, the peptide of SEQ ID NO: 1 was treated at concentrations of 10, 30, 50, 100, and 150ug / ml, and then incubated for 3 days. After removing the medium, CCK-8 solution (Dojindo, CCK-8 kit) was diluted 10-fold into the culture medium and treated in 100ul portions. During incubation at 37°C, the absorbance at 450nm wavelength was measured using a microplate reader at 30-minute intervals.

[0110] As a result, when the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention was treated, the absorbance was higher, confirming that the peptide of the present invention does not exhibit toxicity in mouse macrophages (see FIG. 10b).

[0111] <9-3> Confirmation of the inhibitory effect of the peptide of the present invention on TRAP activity associated with osteoclast differentiation Mouse RAW264.7 cell line, 1.7 x 10 3 After dispensing into a 96-well plate at a density of cells / well, the cells were cultured in DMEM medium for 24 hours. After 24 hours, the cells were treated with RANKL and peptide of SEQ ID NO: 1 at concentrations of 10, 30, 50, 100, and 150ug / ml, and then osteoclast differentiation was induced for 4 days. After treatment with 100ul of TRAP activity solution (TRAP buffer (0.1 sodium citrate + 50μM sodium tartrate [pH5.0]) 15ml + 4-nitrophenly phosphate disodium salt hexahydrate, Sigma, 1 tablet mix), the cells were incubated at 37℃ for 1 hour, and then treated with 10ul of 2N NaOH. The absorbance at 405nm wavelength was measured using a plate reader.

[0112] As a result, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention inhibited the activity of TRAP, an osteoclast marker, in mouse macrophages in a concentration-dependent manner (see FIG. 10c).

[0113] [Experimental Example 10] Confirmation of the inhibitory effect of RANKL on osteoclast differentiation Mouse RAW264.7 cell line, 1.7 x 10 3 After dispensing into a 96-well plate at a density of cells / well, the cells were cultured in DMEM medium for 24 hours. After 24 hours, the cells were treated with peptide of SEQ ID NO: 1 at concentrations of 50 and 100 together with RANKL, and then osteoclast differentiation was induced for 4 days. After removing the medium on the first day of induction, the cells were harvested and cell lysates were prepared, followed by Western blotting using an antibody against NFATc1 protein (Millipore, USA).

[0114] As a result, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO:1 of the present invention inhibits the production of NFATc1 protein, which is the main transcription factor in the process of differentiation of adipose-derived mesenchymal stem cells into osteoclasts (see FIG. 11).

[0115] [Experimental Example 11] Confirmation of inhibition of actin ring formation in osteoclasts induced by RANKL In addition to the results of Experimental Examples 9 and 10, in order to further confirm the inhibitory effect of osteoclast differentiation by treatment with the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention, mouse RAW264.7 macrophage cell line was treated with RANKL to induce differentiation into osteoclasts, and it was confirmed whether the peptide of the present invention inhibits the formation of actin rings, which are essential for osteoclast differentiation.

[0116] For this purpose, the mouse RAW264.7 cell line was cultured at 5 × 10 3After distributing the cells into a 96-well plate at a density of cells / well, the cells were cultured in DMEM medium for 24 hours. After 24 hours, the cells were treated with RANKL and peptide of SEQ ID NO:1 at concentrations of 50 and 100ug / ml, and then osteoclast differentiation was induced for 4 days. After removing the medium, the cells were washed three times with chilled PBS and fixed with 4% paraformaldehyde for 30 minutes. After washing three times for 5 minutes with chilled PBS, the cells were permeated with 0.3% Triton X-100 in PBS for 30 minutes. After washing three times for 5 minutes with chilled PBS, the cells were blocked with filtered 3% BSA in PBS for 1 hour under agitation. Primary antibody (Rhodamin (Red) [Invitrogen] diluted 1:100 in blocking medium was added to the cells, and the cells were incubated for 3 hours at 4°C for 1 hour. After washing three times for 5 minutes with chilled PBS, the cells were blocked with filtered 3% BSA in PBS under agitation for 1 hour. TM ]) for 2 hours under agitation. After blocking light and washing with PBS three times for 15 minutes under agitation, DAPI mounting medium (VECTASHIELD(R) MOUNTING MEDIUM with DAPI) was added, and each well was covered with a cover slip and observed under a microscope.

[0117] As a result, it was confirmed that the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention inhibited the formation of actin rings, which are essential for differentiation into osteoclasts in mouse macrophages (see FIG. 12).

[0118] Considering the results of Experimental Examples 9 and 11, it can be confirmed that the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention can inhibit differentiation into osteoclasts, and thus can be applied to the prevention or treatment of osteoporosis. In addition, when a larger amount of the peptide of the present invention is used, the above-mentioned effect is more pronounced, and therefore it can be seen that the osteoclast differentiation inhibitory effect seen from the results of the above-mentioned Experimental Examples is due to the peptide of the present invention.

[0119] [Production Example 1] Production of pharmaceutical composition <1-1> Manufacturing of powders 2g of peptide of Example 1 1g lactose The ingredients were mixed and filled into an airtight bag to prepare a powder.

[0120] <1-2> Tablet manufacturing 100 mg of the peptide of Example 1 Corn starch 100mg Lactose 100mg Magnesium stearate 2mg The above ingredients were mixed and then compressed into tablets according to a conventional tablet manufacturing method.

[0121] <1-3> Manufacturing of capsules 100 mg of the peptide of Example 1 Corn starch 100mg Lactose 100mg Magnesium stearate 2mg After the above ingredients were mixed, they were charged into a gelatin capsule according to a conventional capsule manufacturing method to prepare a capsule.

[0122] <1-4> Ring manufacturing Peptide of Example 1 1g Lactose 1.5g 1g glycerin Xylitol 0.5g The above ingredients were mixed and then prepared according to a conventional method so that each ring had a weight of 4 g.

[0123] <1-5> Granule manufacturing 150 mg of the peptide of Example 1 Soybean extract 50mg Glucose 200mg Starch 600mg After mixing the above ingredients, 100mg of 30% ethanol was added and dried at 60 degrees Celsius to form granules, which were then filled into sachets.

[0124] [Production Example 2] Production of functional health food composition <2-1> Manufacturing of flour foods 0.5 to 5.0 parts by weight of the peptide of Example 1 was added to wheat flour, and the mixture was used to produce bread, cakes, cookies, crackers and noodles.

[0125] <2-2> Production of soups and gravies 0.1 to 5.0 parts by weight of the peptide of Example 1 was added to soup and gravy to produce health-promoting processed meat products, noodle soup and gravy.

[0126] <2-3> Dairy product production 5-10 parts by weight of the peptide of Example 1 was added to milk, and various dairy products such as butter and ice cream were produced using the milk.

[0127] <2-4> Zen food production Brown rice, wheat, glutinous rice, and barley were gelatinized and dried using a known method, then roasted and milled into powder with a particle size of 60 mesh. Black beans, black sesame seeds, and perilla seeds were also steamed and dried using a known method, then roasted and milled into powder with a particle size of 60 mesh. The grains, nuts, and seeds prepared above and the peptide of Example 1 were mixed in the following ratios to produce the product.

[0128] Grains (brown rice 30 parts by weight, pearl barley 15 parts by weight, barley 20 parts by weight), nuts and seeds (perilla 7 parts by weight, black soybeans 8 parts by weight, black sesame 7 parts by weight), peptide of Example 1 (3 parts by weight), Ganoderma lucidum (0.5 parts by weight), Rehmannia husk (0.5 parts by weight) <2-5> Manufacturing of health drinks Subsidiaries such as liquid fructose (0.5%), oligosaccharides (2%), sugar (2%), salt (0.5%), and water (75%) were homogeneously mixed with 5 g of the peptide of Example 1 and flash sterilized, and then the mixture was packaged in small packaging containers such as glass bottles and PET bottles to produce the product.

[0129] Although the present invention has been described in detail above only with respect to the described embodiments, it will be apparent to those of ordinary skill in the art that various modifications and variations are possible within the scope of the technical concept of the present invention, and it is natural that such modifications and variations are included within the scope of the appended claims.

Claims

1. A peptide comprising the amino acid sequence of SEQ ID NO:

1.

2. The peptide according to claim 1 , which has one or more physiological activities selected from the group consisting of cartilage regeneration activity, anti-inflammatory activity, and osteoporosis suppression activity.

3. The peptide of claim 1 , wherein the peptide promotes differentiation of stem cells into chondrocytes.

4. The peptide according to claim 3 , wherein the stem cells are at least one selected from the group consisting of umbilical cord blood-derived stem cells, peripheral blood-derived stem cells, bone marrow-derived stem cells, and mesenchymal stem cells.

5. The peptide of claim 1, wherein the peptide increases the synthesis of extracellular matrix (ECM) in chondrocytes.

6. The peptide according to claim 1, wherein the peptide increases the expression of one or more genes selected from the group consisting of collagen type II (COL2A1), ACAN (aggrecan), and PCP (Proteoglycan Core Protein) in chondrocytes.

7. The peptide of claim 1 , wherein the peptide inhibits expression of inflammatory cytokines.

8. The peptide according to claim 7, wherein the inflammatory cytokine is one or more selected from the group consisting of TNFα, IL-1β, COX2, IL-6, IL-17, and IFNγ.

9. The peptide of claim 1 , which inhibits differentiation of macrophages into osteoclasts.

10. A pharmaceutical composition for cartilage regeneration comprising the peptide according to any one of claims 1 to 9 as an active ingredient.

11. A pharmaceutical composition for preventing or treating an inflammatory disease, comprising the peptide according to any one of claims 1 to 9 as an active ingredient.

12. A pharmaceutical composition for preventing or treating osteoporosis, comprising the peptide according to any one of claims 1 to 9 as an active ingredient.

13. A health functional food for cartilage regeneration, comprising the peptide according to any one of claims 1 to 9 as an active ingredient.

14. A health functional food for preventing or improving an inflammatory disease, comprising the peptide according to any one of claims 1 to 9 as an active ingredient.

15. A health functional food for preventing or improving osteoporosis, comprising the peptide according to any one of claims 1 to 9 as an active ingredient.

Citation Information

Patent Citations

  • Rapid Biopanning Assay for Selective Interacting Ligands (brasil)

    JP2004530404A